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In HIV-1, the ability to mount antibody responses to
conserved, neutralizing epitopes is critical for pro-
tection. Here we have studied the light chain usage
of human and rhesus macaque antibodies targeted
to a dominant region of the HIV-1 envelope second
variable (V2) region involving lysine (K) 169, the site
of immune pressure in the RV144 vaccine efficacy
trial. We found that humans and rhesus macaques
used orthologous lambda variable gene segments
encoding a glutamic acid-aspartic acid (ED) motif
for K169 recognition. Structure determination of an
unmutated ancestor antibody demonstrated that
the V2 binding site was preconfigured for ED motif-
mediated recognition prior to maturation. Thus, light
chain usage for recognition of the site of immune
pressure in the RV144 trial is highly conserved across
species. These data indicate that the HIV-1 K169-
recognizing EDmotif has persisted over the diversifi-
cation between rhesus macaques and humans,
suggesting an evolutionary advantage of this anti-
body recognition mode.
INTRODUCTION
The RV144 vaccine trial showed an estimated vaccine efficacy of
31% (Rerks-Ngarm et al., 2009), and a molecular sieve analysis
of breakthrough infections demonstrated 48% vaccine efficacyI
when the second variable region (V2) of the infecting virus enve-
lope (Env) matched the vaccine Env at lysine (K) at position 169
(Rolland et al., 2012). Isolation of V2 monoclonal antibodies
(mAbs) from vaccinees demonstrated that in four V2 antibodies
that recognized K169, all light chain second complementarity
determining regions (LCDR2) contained a glutamic acid-aspartic
acid (ED) motif, and crystal structures of two K169-reactive hu-
man mAbs, CH58 and CH59, demonstrated salt bridges formed
with K169 by the E of CH58 and the D of CH59 (Liao et al., 2013).
Of the four V2 antibodies initially isolated from RV144 vaccinees,
mAb CH58 utilized lambda light chain V gene segment 6-57
(IGLV6-57) and mAb CH59 utilized IGLV3-10, both of which
have a germline-encoded ED motif (Lefranc, 2001). Two addi-
tional V2 K169 antibodies, HG107 and HG120, independently
isolated from RV144 vaccinees also expressed IGLV3-10 light
chains and retained the LCDR2 EDmotif (Liao et al., 2013). These
observations raised the hypothesis that Vl gene segments car-
rying the LCDR2 ED motif were required to recognize the
HIV-1 V2 K169 epitope and exert the selective pressure apparent
in the RV144 vaccine trial (Liao et al., 2013).
Rhesus macaques have been useful models of retrovirus
infection pathogenesis as well as for evaluation of protective
capacity of antibodies against simian immunodeficiency virus
(SIV) and simian-human immunodeficiency virus (SHIV) infec-
tions. Study of the rhesus macaque genome has demonstrated
that humans and rhesus macaques share 93% of genome
homology (Gibbs et al., 2007), with a common ancestor esti-
mated at 32 million years ago (Perelman et al., 2011). Thus,
study of the rhesus antibody repertoire as a model for how
humans will respond to pathogens and vaccines might be a
useful approach for the prediction of human antibody
responses.mmunity 41, 909–918, December 18, 2014 ª2014 Elsevier Inc. 909
Figure 1. Antigen-Specific Memory B Cell Sorts on Peripheral Mononuclear Blood Cells from Three Nonhuman Primate Studies
Live CD14CD16CD20+CD3IgDCD27+ cells were stained with antigens conjugated to two different fluorophores. Double-positive antigen-specific cells were
single-cell sorted into 96-well PCR plates for RT-PCR. AE.A244 gp120-specific memory B cells were (A) 3.0% of NHP study 36 and (B) 1.2% of NHP study 62.
NHP study 53 (C) was sorted with CAP206 T/F gp140 and 0.36% of cells were specific for this HIV-1 envelope. Data are representative results of at least three
independent experiments.
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Phylogenetic Conservation of HIV-1 V2 RecognitionOne route to improvement on the results of the RV144 vaccine
trial is to determine whether any VL genes other than IGLV6-57
and IGLV3-10 can be used to target the K169 V2 region. To
address this question, we immunized rhesus macaques with the
RV144 vaccine Env, AE.A244 gp120, and isolated 27 antibodies
that are dependent on V2 K169 for binding to HIV-1 Env gp120.
We found that all 27 antibodies utilized the rhesus ortholog of
human IGLV3-10, i.e., the rhesus IGLV3-17 gene segment that
containsagermline-encodedLCDR2EDmotif. Twoadditional an-
tibodies were isolated from rhesus immunizations with clade C
Envs that recognized V2 K169 that were not IGLV3-17, but rather
had EDmotifs derived from LCDR2 somatic mutations. Thus, the
only observedmechanismof recognitionofK169 inprimates is via
antibodies with lambda light chains with a LCDR2 ED motif. That
this germline-encoded rhesus IGLV3-17 and human IGLV3-10
light chain mode of recognition of V2 K169 has persisted through
the divergence of humans and rhesus macaques suggests that
the Vl LCDR2 ED motif confers a strong fitness advantage.
RESULTS
Restricted Utilization of Rhesus Macaque IGLV3-17
in Recognition of HIV-1 Env V2 K169
We immunized rhesus macaques with the RV144 vaccine trial
Env AE.A244 gp120 in two regimens, one with the same immu-
nogens used in the RV144 trial (Rerks-Ngarm et al., 2009)
(NHP study 36; Figure S1A available online), and the other with
a heterologous prime-boost strategy with RV144 AE.A244
gp120 Env glycoprotein immunogen as a prime, followed
sequentially by AE.427299 gp120, B.9021 gp140, AE.A244
gp120, and then a final boost of AE.A244 and AE.427299
gp120s (NHP study 62.1; Figure S1B). Env proteins 92TH023
gp120 and CM244 gp120 in NHP study 36 and AE.A244 gp120
in NHP study 62.1 included K169 in their V2 loops whereas
Env proteins MN.3 gp120 in NHP study 36 and AE.427299
gp120 and B.9021 gp140 in NHP study 62.1 did not (Gnanakaran
et al., 2010; Liao et al., 2013).
We isolated antibodies from immunized monkeys utilizing an-
tigen-specific memory B cell sorts with fluorophore-labeled910 Immunity 41, 909–918, December 18, 2014 ª2014 Elsevier Inc.AE.A244 gp120 (Bonsignori et al., 2012) or similarly labeled
AE.A244 V1V2 tags protein (Liao et al., 2013) (Figure 1). A total
of 39 antibodies were isolated that bound to the V2 region of
Env (165LRDKKQKVHALFYKLDIVPIED186) in ELISA assays from
NHP studies 36 and 62.1 (Tables S1 and S2). Of the 39 V2-tar-
geted antibodies, 27 antibodies bound at K169 (the site of im-
mune pressure in the RV144 vaccine efficacy trial) as established
by alanine scanning binding ELISA assays (Table S1). All 27 V2
K169-dependent antibodies utilized IGLV3-17 genes with an
ED motif in the LCDR2 (Table S2).
Next, we selected a set of 18 V2-reactive antibodies with an
ED motif for production in bulk and further characterization.
Extensive epitope mapping by alanine-scanning mutagenesis
with a 19-residue AE.A244 V2 peptide (165LRDKKQKVHALFYKL
DIVPIED186) confirmed that all 18 EDmotif-containing antibodies
demonstrated K169-dependent binding (Table 1, Figure S2). All
antibodies also had H173 as an epitope component and addi-
tionally had combinations of K171, F176, Y177, and D180 amino
acids in their epitopes. The epitopes recognized by the rhesus
antibodies were most similar to the epitope utilized by the previ-
ously described human mAb, CH59, derived from an RV144
vaccinee (Liao et al., 2013).
We then characterized the neutralization breadth of the 18
K169-recognizing, ED motif antibodies by using both TZM-bl
and A3R5 HIV-1 neutralization assays (McLinden et al., 2013;
Sarzotti-Kelsoe et al., 2014). All 18 antibodies neutralized the
easy-to-neutralize tier 1 virus AE.92TH023.6 in the TZM-bl assay
(Table S3) but failed to neutralize the tier 1 HIV-1 isolate MN.3
(which does not have a K at position 169) and difficult-to-
neutralize tier 2 HIV-1 isolate AE.CM244 in TZM-bl. All but one
antibody failed to neutralize any HIV-1 isolates tested in the
A3R5.7 cell assay (Table S3).
We next confirmed the EDmotif as critical to V2 recognition by
making single (D51A)- and double (E50A+D51A)-alanine muta-
tions by site-directed mutagenesis to antibody 1518, a separate
rhesus antibody from NHP 36 that was not included in the char-
acterization above. Binding to AE.A244 gp120, V1V2 tags, and
V2 peptide was reduced for the single-alanine mutant and
greatly reduced for the double-alanine mutant (Table S1B).
Table 1. V2 Epitopes of Selected Antibodies
Antibody Species VH VL V2 Epitope
1678 rhesus 3-SC11 l3-17 K169*, H173, F176, Y177
1697 rhesus 3-SC11 l3-17 K169*, H173, F176, Y177
1811 rhesus 3-SC11 l3-17 K169*, H173, D180
1410 rhesus 4-48 l3-17 K169*, H173, D180
1825 rhesus 4-48 l3-17 K169*, H173
2552 rhesus 4-48 l3-17 K169*, H173
975 rhesus 4-79 l3-17 K169*, K171, H173, Y177,
D180
1447 rhesus 4-79 l3-17 K169*, H173, Y177, D180
1601 rhesus 4-79 l3-17 K169*, H173, D180
1671 rhesus 4-79 l3-17 K169*, H173
1819 rhesus 4-79 l3-17 K169*, H173, Y177
1823 rhesus 4-79 l3-17 K169*, H173, Y177, D180
1824 rhesus 4-79 l3-17 K169*, H173, Y177, D180
2553 rhesus 4-79 l3-17 K169*, H173, D180
2536 rhesus 4-96 l3-17 K169*, H173, D180
2547 rhesus 4-96 l3-17 K169*, H173, F176
2653 rhesus 4-96 l3-17 K169*, H173, D180
2548 rhesus 4-SC6 l3-17 K169*, H173, D180
1056a rhesus 3-SC11 l3-SC4 K169*, K171, H173, F176,
Y177, D180
1534a rhesus 3-SC11 l3-SC4 K169*, K171, H173, F176,
Y177, D180
CH58b human 5-51 l6-57 K168, K169*, K171, H173,
F176, Y177, K178, D180,
P183
CH59b human 3-9 l3-10 K169*, H173, F176, Y177,
D180
HG107b human 3-9 l3-10 K169*, K171, H173, F176,
Y177, D180
HG120b human 3-23 l3-10 K169*, H173, F176, Y177,
D180
V2 epitope residues were defined as residues where EC50 relative to WT
for alanine mutations was reduced by >50% in ELISA assay. Epitope po-
sitions determined by ELISA were also confirmed by SPR for representa-
tive set of mutations (same as listed below). K169, the site of immune
pressure in the RV144 trial, is indicated with an asterisk (*).
aAntibody footprints mapped by SPR only for mutations K168A, K169A,
K171A, H173A, F176A, Y177A, and D180A.
bAntibody footprints previously described (Liao et al., 2013).
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mutants (Table S3). Taken together, these data demonstrate
that the ED motif was essential for recognition of the V2 loop
and mediation of neutralization.
The predominance of EDmotif-containing antibodies in the V2
response suggested that the V2 is strongly antigenic for naive B
cell receptors utilizing IGLV3-17. We computationally inferred
the initial V(D)J rearrangements of three representative IGLV3-
17, ED-motif-containing antibody clonal lineages (Kepler, 2013)
and recombinantly produced them for characterization. All three
unmutated common ancestor (UCA) antibodies demonstrated
binding to AE.A244 V1V2 tags protein with binding of two of
the three UCAs reduced relative to the corresponding mutatedI
antibodies (Table S1C). No neutralization was observed for the
three UCAs (Table S3), demonstrating that the neutralization ca-
pacity of IGLV3-17 V2 antibodies is not attained until additional
mutations are acquired from affinity maturation.
Acquisition of LCDR2 ED Motif via Affinity Maturation
We next asked whether we could observe examples of V2 K169
antibodies induced without the utilization of the CDRL2 EDmotif
encoding IGLV3-17 gene from regimens from other NHP studies.
For this analysis we isolated antibodies from a rhesus macaque
that was immunized with three clade C (CAP206) Envs that each
had a lysine at position 169 in V2 (NHPStudy 54, Figure S1C).We
isolated two antibodies (1056 and 1534) that bound AE.A244 V2
peptide that were dependent for their binding on K169 (Table 1
and Figure S2) and had an ED motif in LCDR2. However, these
two antibodies did not use IGLV3-17, but rather used the
IGLV3-SC4 gene segment that encodes a KD amino acid pair
in the germline LCDR2 (Figure 2A). This K50E mutation in the
1056 and 1534 antibodies was probably the result of VJ hyper-
mutation in germinal centers.
We next asked whether the K50E mutation resulted in
improved Env binding. We used site-directed mutagenesis to
revert E50 in the LCDR2s of antibodies 1056 and 1534 back to
K. Indeed, we found that binding to the CAP206 transmitted-
founder gp140 improved 4- to 6-fold for the ED-bearing 1056
and 1534 antibodies compared to 1056 and 1534 E50K reversion
mutants (Figure 2B). Although wild-type E50 antibodies 1056
and 1534 bound well to AE.A244 gp120 and the AE.A244 V1V2
tag subunit protein, binding was lost or greatly diminished to
these antigens in the E50K reverted antibodies (Figure 2B). Addi-
tionally, neutralization of the tier 1 HIV-1 strain C.MW965.26 was
substantially reduced for 1534 E50K and lost for 1056 E50K (Fig-
ure 2C), demonstrating that acquisition of the ED motif resulted
in the gain of heterologous tier 1 HIV-1 neutralization capacity.
Limited Availability of LCDR2 ED Motif in the Antibody
Repertoires of Humans and Rhesus Macaques
Thus, 71% (29/41) of the total number of V2 antibodies and 58%
(15/26) of the V2-reactive clonal lineages isolated from three rhe-
sus macaque Env immunization studies bound at K169, and all
29 K169-recognizing antibodies included the CDRL2 ED motif
either by using IGLV3-17 in which ED is germline encoded (27
MAbs), or by acquiring ED through somatic mutations (2 MAbs)
(Figure 3). Given the remarkable usage of the ED motif for
K169 recognition in both the human and rhesus immune
response to HIV-1 Env immunization, we next asked how
frequently the LCDR2 EDmotif is encoded in the human and rhe-
sus macaque light chain repertoires.
In humans, the LCDR2 ED motif is encoded in three Vl gene
segments: IGLV3-10, IGLV6-57, and IGLV3-22. IGLV3-22 has
two alleles: IGLV3-22*02 is a pseudogene with a frame-shift mu-
tation producing a premature stop codon and IGLV3-22*01 is
potentially functional (Frippiat and Lefranc, 1994; Lefranc,
2001). IGLV3-22 has not, however, been observed in lambda re-
arrangements in GenBank antibody sequences, suggesting that
the dominant allele is IGLV3-22*02 that effectively restricts
germline encoding of the ED motif in the human repertoire to
two light chain Vl gene segments, IGLV6-57 and IGLV3-10.
These two gene segments were precisely those utilized by themmunity 41, 909–918, December 18, 2014 ª2014 Elsevier Inc. 911
Figure 2. CDRL2 ED Motif Can Be Acquired by Affinity Maturation
(A) Amino acid sequence alignment of VL region of antibodies 1056 and 1534 to their inferred germline VL gene segment. IGLV3-SC4 shows that K50E somatic
hypermutation confers the ED motif (red). Dots represent amino acid matches to germline. The ED motif is bolded for emphasis.
(B) ELISA binding results for clonally related WT antibodies 1056 and 1534 and reverted E50K mutants tested against CAP206 (autologous) and A244 antigens.
(C) Neutralization of clade C tier 1 MW965.26 in TZM-bl cell assay (orange denotes neutralization at <50 mg/ml).
Data are from one experiment (B and C) with neutralization values (C) representing the average of duplicate measurements.
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Phylogenetic Conservation of HIV-1 V2 Recognitionhuman V2K169 antibodies isolated fromRV144 vaccinees (n = 4)
(Liao et al., 2013).
The known rhesus macaque light chain repertoire includes
only two light chain V gene segments that encode for the
LCDR2 ED motif in the germline, IGLV3-17 and IGLV3-30. Rhe-
sus IGLV3-17 is an ortholog of human IGLV3-10 and the gene
segments share 97% sequence similarity (Figure 4, Table S4).
IGLV3-30 is an ortholog of human IGLV3-22. As with human
IGLV3-22, no IGLV3-30 antibodies have been observed in Gen-
Bank. However, the incomplete characterization of rhesus Ig
gene segments prevents us from establishing whether nonfunc-
tional alleles for this gene segment exist. The rhesus ortholog of
human IGLV6-57 is IGLV6-92, but IGLV6-92 encodes for a KD in
its LCDR2. It is important to note that characterization of the rhe-
sus Ig gene segment repertoire is incomplete, and it is possible
that more gene segments or alleles that include an ED motif in
the LCDR2 might be defined in the future.
Conservation of the IGLV3-10 V Gene Segment in
Primate Phylogeny
Becausewe have observed antibodies containing the LCDR2ED
motif in both human and rhesus antibody responses to HIV-1 V2
K169 and found that the ED motif is encoded in the germline Vl912 Immunity 41, 909–918, December 18, 2014 ª2014 Elsevier Inc.segments of both species, we next askedwhether the EDmotif is
present in the Vl gene segments of other primates. We searched
for all human IGLV3-10 orthologs within 12 primate genomes.
The genomes queried consisted of a diverse set of primates
including representatives from the groups of great apes, old
world monkeys, new world monkeys, tarsiers, and lemurs. All
12 primate genomes contained IGLV3-10 orthologs and in all
but two (Pongo abelii and Saimiri boliviensis), the LCDR2 ED
motif was present within their respective IGLV3-10 ortholog (Fig-
ure 5A). Within great apes, bonobos, and old world monkeys, the
orthologs are highly similar to human IGLV3-10 with sequence
identities greater than 95% (Figure 5B). Sequence identities of
orthologs in themore distant extant primate groups of newworld
monkeys, tarsiers, and lemurs are between 84% and 89%.
Rhesus macaque and humans shared a common ancestor an
estimated 32 million years ago (Perelman et al., 2011), demon-
strating that the IGLV3-10 gene segment has not been altered
substantially and has maintained the ED motif over that time
period (Figure 5B). Given the presence of the ED motif in the
mouse lemur (Microcebus murinus) light chain repertoire, the
conservation of the EDmotif in the primate lineage can be traced
as far back as an estimated 87 million years ago (Perelman et al.,
2011). The ED motifs in the IGLV3-10 primate orthologs are
Figure 3. All K169-Dependent V2Antibodies
Contain the CDRL2 ED Motif
Summary of characteristics of the rhesus anti-
bodies. Antibody names are labeled in the
segments of the outer ring for antibodies with V2-
binding reactivity (red). Segments proceeding
inward toward center indicate additional charac-
teristics of the antibody. The first inner ring spec-
ifies K169-dependent V2 recognition (blue) and
second inner ring specifies presence of LCDR2 ED
motif (green). The innermost ring specifies IGLV3-
17 germline usage (magenta) or ED motif gained
by somatic hypermutation (SHM) (cyan). Gray
segments denote antibodies without the specified
characteristic at that ring level. Data are repre-
sentative of two independent experiments for
purified antibodies and one experiment for anti-
bodies from initial primary screening (see Table S1
for breakdown).
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ure S3) with heterogeneity in codon usage observed in the
more distant primate species from human, providing further ev-
idence of a strong selective pressure for maintenance of the ED
motif.
Structural Insights into Germline IGLV3-10 Usage and
K169 Recognition
In order to gain structural insights into IGLV3-10 usage and V2
K169 recognition, we determined the crystal structure of the
CH59 unmutated ancestor (CH59-UA) antibody that utilizes the
germline IGLV3-10 segment (Figure 6A, Table S5). CH59-UA
binds with micromolar affinity to the AE.A244 V2 peptide (Kd =
0.5 mM), a value two orders of magnitude weaker than the affinity
of the mutated CH59 antibody (Kd = 3.1 nM) (Figure S4). Super-
position of the CH59-UA structure onto the structure of mature
CH59 in complex with a V2 peptide (Liao et al., 2013) revealed
that the CH59 V2 K169 binding site is remarkably similar to the
corresponding paratope of CH59-UA (Figure 6B). The average
backbone root mean square deviation (rmsd) of the six CDRs
was 1.26Å with the light chain CDRs aligning more closely
(0.88Å rmsd) than the heavy chain CDRs (1.52Å rmsd). Particu-
larly striking was the structural similarity between the respective
ED motif conformations in the unliganded CH59-UA and theI
bound mature CH59. The CH59-UA E50 and D51 side chains
are positioned in nearly identical orientations as the bound con-
formations of the corresponding side-chains in themature CH59,
demonstrating in an unliganded and germline IGLV3-10 antibody
that the ED motif is in precisely the orientation used for recog-
nizing K169 V2. Taken together, these data show that the
CH59 binding site is largely preconfigured in the unliganded
CH59-UA. Preconfiguration of an antibody binding site can miti-
gate the entropic penalty paid upon association (Schmidt et al.,
2013), and consistent with this prediction, the CH59-UA has a
very fast on-rate (Figure S4). The on-rate of the CH59-UA was
observed to be similar to that of the mature CH59 on-rate;
consequently, affinity maturation in the CH59 lineage is driven
by off-rate improvements. Given that rhesus IGLV3-17 has
97% sequence identity to human IGLV3-10, we expect that the
germline structure of rhesus IGLV3-17 is probably identical to
the structure of human IGLV3-10. Consequently, the light chain
recognition mode of rhesus IGLV3-17 antibodies to the HIV-1
V2 K169 epitope must closely resemble light chain recognition
in the CH59 antibody lineage.
All rhesus macaque V2 antibodies isolated that contain the
ED motif have LCDR3 lengths of 11 residues (Table S2), the
same length as the LCDR3 of the human RV144 trial vaccine
antibody, CH59. We next asked how compatible the EDFigure 4. Rhesus Orthologs of Human VLs
Encoding for CDRL2 ED Motif in the Germ-
line
Amino acid sequence alignments of the rhesus VL
orthologs to human IGLV3-10 and IGLV6-57. Dots
represent amino acid residue matches. The ED
motif is bolded and colored red for emphasis.
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Figure 5. Conservation of IGLV3-10 and ED
Motif in Primate Phylogeny
(A) Amino acid sequence alignment of human
IGLV3-10 to orthologs from 12 primates with
sequenced genomes. Dots represent amino acid
residue matches and residues in the LCDR2 ED
motif positions are bolded for emphasis.
(B) Sequence identities of primate IGLV3-10 or-
thologs to human IGLV3-10 (right) juxtaposed to
phylogenetic tree including respective primate
species (left). Data on estimated time (in millions of
years ago) to most common recent ancestor
(shown in bold on tree nodes for relevant esti-
mates) as well as for phylogenetic tree were taken
from Perelman et al. (2011). Branch length esti-
mate units are substitution/site.
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with V2 (Liao et al., 2013). We threaded the sequence of a
representative ED motif-containing rhesus antibody, Ab975,
onto the CH59-V2 peptide complex structure, and the struc-
tural model of Ab975 demonstrated agreement with the
CH59 mode of V2 recognition (Figure S4E). The ED motif of
Ab975 is predicted to adopt a similar orientation as CH59, sug-
gesting that the ED motif of Ab975 could also form salt bridges
with K169 and K171, which is consistent with the epitope map-
ping of Ab975 (Table 1). The binding pocket opposite the
C-terminal half of the V2 peptide in the structural model of
Ab975 is shallower than CH59’s binding pocket, most likely re-
flecting differences in the heavy chain usage between Ab975
and CH59.
Analysis of Rhesus Macaque VH Pairing with IGLV3-17
ED Antibodies
All IGLV3-17 ED-motif-containing antibodies shared the amino
acid H173 in their V2 epitopes (Table 1). In the crystal structure
of the complex of CH59 with a V2 peptide, the heavy chain con-
tacted residues C-terminal of K169 with H173 forming hydrogen
bond contacts with Asp 95 (D95) in the heavy chain (Liao et al.,
2013). Although VH pairing with IGLV3-17 does not appear to
be overly restricted, with four distinct VH gene segments used
among 15 IGLV3-17 clones (Table S2), all IGLV3-17 antibodies
isolated contained D95, like CH59 (Figure S5), suggesting that
D95 might play a functional role in their V2 recognition. Because
of the incomplete characterization at the 30 end of VH gene seg-
ments in the rhesus repertoire, we cannot be certain about the
frequency in which D95 is encoded in heavy chains and whether
this structural feature represents an additional restriction for
recognition of the V2 epitope.
It is notable, however, that we have not observed the CH59
IGHV3-9 rhesus ortholog, IGHV3-78 (Table S4B), paired with
the IGLV3-17 of the rhesus ED motif antibodies. We hypothe-
sized that the lack of rhesus heavy and light chain pairs that914 Immunity 41, 909–918, December 18, 2014 ª2014 Elsevier Inc.were orthologous to the CH59 pairing
could be due to incompatibly of the
IGHV3-78 sequence in the CH59 V2
recognition mode. A structural model of
IGHV3-78:IGLV3-17 in the CH59 recogni-
tion mode resulted in severe clashing be-tween the Y59 residue in the HCDR2 and the V2 peptide (Fig-
ure S4F). In CH59, the IGHV3-9 germline gene does not
encode a large amino acid such as tyrosine but instead the
smallest amino acid residue, glycine, which allows for favorable
paratope shape complementarity with the V2 peptide. Thus, the
steric hindrance of IGHV3-78 with the V2 peptide when structur-
ally modeled into the CH59 recognition mode suggests a poten-
tial explanation for why we do not observe IGHV3-78:IGLV3-17
pairing in the rhesus V2 antibody response.
DISCUSSION
In this study, we demonstrate that the dominant antibody
response in recognition of the V2 epitope surrounding lysine at
amino acid position 169 in rhesus macaques utilizes the
IGLV3-17 gene segment with a LCDR2 ED amino acid pair. We
show that the VL ED motif can arise either by being encoded in
the IGLV3-17 germline gene or arise in the course of somatic mu-
tation from a germline-encoded KD LCDR2 motif. Remarkably,
the rhesus IGLV3-17 gene is the ortholog of the human IGLV3-
10 gene, which is utilized for recognition of the V2 K169 site in hu-
mans (Liao et al., 2013).
The rhesus IGLV3-17 ED motif antibodies had very similar
neutralization profiles as human ED motif Abs CH58 and CH59,
and rhesus ED motif Ab V2 footprints were most consistent
with the V2 epitope of human V2 mAb CH59. The epitope foot-
prints of human RV144 vaccinee V2 antibodies HG107 and
HG120 were also similar to CH59, and all three antibodies
used the IGLV3-10 gene segment, demonstrating that human
IGLV3-10 and rhesus IGLV3-17 ortholog usage confers a highly
consistent V2 recognition mode in both human and rhesus anti-
V2 antibodies.
Of the four distinct VH gene segments observed to pair with
IGLV3-17, two pairings, IGHV4-48:IGLV3-17 and IGHV4-
79:IGLV3-17, occurred independently in two monkeys given
two different immunization regimens. In addition, one VH:VL
Figure 6. CH59-UA Structure Reveals Pre-
configured K169 Recognition Mode in
IGLV3-10 Germline
(A) Crystal structure of the CH59-UA Fab with
heavy chain colored blue and light chain colored
green. See Table S5 for summary of structural
data.
(B) Superposition of crystal structures of CH59-UA
(magenta) andmature CH59 (gray) in complex with
a V2 peptide (cyan). The EDmotif in CDRL2 of both
antibodies and K169 and K171 of V2 peptide are
shown in stick representation. Dashed lines indi-
cate salt bridges in mature CH59-V2 complex.
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K169-recognizing ED motif antibody HG120 isolated from an
RV144 subject. These data demonstrated that although there
are many solutions to the problem of epitope recognition, the
antibody response can enlist common modes of recognition
through preferential VH:VL pairing. Although VH:VL pairing is
thought to be largely a stochastic process (de Wildt et al.,
1999; Jayaram et al., 2012), the selection process itself is not
random and those pairings that result in high-affinity binding of
antigen by the naive BCR will be preferentially selected (Dal
Porto et al., 1998; Shih et al., 2002). In HIV-1 infection, restricted
pairing among different individuals has previously been reported
for the VRC-01 CD4 binding site class of bnAbs where IGHV1-2
or IGHV1-46 must pair with light chain VJ rearrangements with a
very short LCDR3 (West et al., 2012) in order to mimic CD4 in
binding to the gp120 CD4 binding site at the correct angle for
broad neutralization (Zhou et al., 2013). An additional example
of restricted pairing in the HIV-1 antibody response is the
VH:VL pairing of IGHV1-69:IGKV3-20, which has been observed
for two gp41 neutralizing antibodies, 4E10 and CAP206-CH12
(Morris et al., 2011; Zwick et al., 2001), that recognize a similar
MPER epitope. Unlike in broadly neutralizing HIV-1 antibodies
(Haynes et al., 2012b), the ED motif antibodies have low levels
of somatic mutations. Therefore, although the ED motif-contain-
ing antibodies are associated to date with a low level of vaccine
efficacy (Haynes et al., 2012a; Liao et al., 2013; Rerks-Ngarm
et al., 2009), they are readily inducible, making the ED antibody
response a desirable type of vaccine-induced response. One
problem with the RV144 vaccine response was the limited
breadth of the V2 response (Rolland et al., 2012). Efforts to
broaden the V2 response with more V2 immunogen motifs will
be one key to improving vaccine efficacy.
Several conformational V2 antibodies with limited neutraliza-
tion have been elicited in HIV-1 infection and described previ-
ously (Gorny et al., 1994, 2012; Mayr et al., 2013). Analysis of
one of these antibodies, 697-D, demonstrated that unlike
CH58 and CH59, V2 binding was not dependent on K169 (Liao
et al., 2013). Additional analysis of published binding data of
six additional infection-derived V2 antibodies showed thatImmunity 41, 909–918, Dnone of the conformational V2 antibodies
were K169 sensitive (Gorny et al., 2012).
Thus, although infection-derived V2 anti-
bodies represent a class of V2 antibodies,
they do not share the same recognitionproperties as the human or rhesus V2 ED-motif-dependent anti-
bodies elicited from vaccination.
It is important to note that ED-motif-bearing antibodies target
the V2 loop at K169 that is also a component of the V1V2-glycan
epitope recognized by the PG9 class of broadly neutralizing an-
tibodies comprised of PG9, PG16, CAP256-VRC26, and CH01
(Kwong andMascola, 2012). This class of bnAbs is characterized
by their extremely long HCDR3s (24–37 amino acids in length),
sulfated tyrosines by posttranslational modification, and recog-
nition of glycans in the V2 loop. The pool of B cells with extremely
long CDRs is thought to be very small with <1% of B cells of
HCDR3s greater than 28 (Briney et al., 2012). In addition, a tyro-
sine within a larger amino acid motif is required for sulfation to
occur (Stone et al., 2009). Taken together, the low likelihood of
these bnAb requirements occurring simultaneously could help
explain the difficulty of eliciting this type of bnAb response.
The observation that ED motif antibodies target a linear V2
epitope and are easy to induce could also act to block elicitation
of PG9-class bnAbs.
Finally, recent estimates have placed primate lentivirus infec-
tion occurring as long as 12 million years ago (Compton and
Emerman, 2013), and lysine at position 169 is relatively well
conserved in Envs of simian immunodeficiency virus strains in-
fecting many primate species (HIV/SIV Sequence Database
http://www.hiv.lanl.gov/content/index). The observation that
IGLV3-10 has highly similar orthologs throughout the primate
lineage that include the ED motif suggests that the ED motif
probably confers an evolutionary advantage within the antibody
response. One hypothesis is that a recent evolutionary driving
factor for ED motif maintenance could be primate retroviral
defense.
EXPERIMENTAL PROCEDURES
Immunization of Rhesus Macaques
Rhesus macaque immunization regimens for NHP studies 36, 54, and 62.1 are
summarized in Figure S1. For NHP study 36, immunizations were given intra-
muscularly five times at weeks 0, 4, 12, 23, and 53 at 5 3 107 pfu per dose of
ALVAC and 600 mg per dose of AIDSVAX B/E gp120 (five rhesus macaques).
Blood, spleen, and terminal ileum, as well as mesenteric, inguinal, anteriorecember 18, 2014 ª2014 Elsevier Inc. 915
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2 weeks after the fifth immunization. For NHP study 54, immunizations were
given intramuscularly seven times at 6 week intervals with 100 mg per dose
(six rhesusmacaques). Blood sampleswere collected at 2weeks after the third
immunization. For NHP study 62.1, immunizations were given intramuscularly
five times at 6 week intervals with 100 mg per dose (six rhesus macaques).
Blood samples were collected at 2 weeks after the fifth immunization. All rhe-
sus macaques were housed at Bioqual (NHP studies 54 and 62.1) and the New
England Primate Research Center, Southborough, MA (NHP study 36). All rhe-
sus macaques were maintained in accordance with the Association for
Assessment and Accreditation of Laboratory Animals with the approval of
the Animal Care and Use Committees of the National Institutes of Health
and Harvard Medical School. Research was conducted in compliance with
the Animal Welfare Act and other federal statutes and regulations relating to
animals and experiments involving animals and adheres to principles stated
in the Guide for the Care and Use of Laboratory Animals, NRC Publication,
2011 edition.
Antibody Isolation
AE.A244 gp120D11 and AE.A244 V1V2 peptides were conjugated with either
AF647 or BV421 (Invitrogen) dyes. Protein quality after conjugations was as-
sessed by flow cytometry for binding to a panel of well-characterized HIV-1-
specific antibodies. Peripheral blood mononuclear cells (PBMCs) of immu-
nized rhesus macaques were stained with AquaVital dye, CD14 (BV570),
CD16 (PE-Cy7), CD3 (PerCP Cy5.5), CD20 (FITC), CD27 (APC-Cy7), and IgD
(PE). Antigen-specific memory B cells were single-cell sorted with a BD
FACS Aria II into 96-well plates containing 20 ml of reverse transcriptase buffer
(RT) by gating on AquaVital dye, CD14, CD16, CD3, IgD, CD20+, CD27+,
BV421 and AF647 double-positive cells. Immunoglobulin (Ig) heavy and light
chain genes (VH and VL) were PCR amplified via a modified version of a pre-
viously described protocol (Liao et al., 2009), optimized for the amplification
of rhesus antibodies (R.Z., unpublished data). The RT reaction was performed
with 0.100 mM of constant region primers IgG, IgM, IgA, IgD, IgE, Igk, and Igl
(Table S6). Primers and RNA were first incubated at 65C for 5 min. The PCR
plate was chilled to 4C and 0.75 mM dNTPs (QIAGEN), SSIII (U) (Invitrogen),
and RNase Out (U) (Invitrogen) was added followed by an incubation at 50C
for 45 min, 55C for 15 min. The cDNA was then amplified with two PCR steps.
In the first step, 5 ml of cDNA, 103 PCR Buffer (QIAGEN), 103 Q Buffer
(QIAGEN), 0.20 mM dNTPs (QIAGEN), MgCl2 (IgH 0.50 mM, Igk 1.00 mM,
Igl 1.50 mM), and 0.125 mM of either IgA1, IgA2, IgD, IgG, IgM, or Igk, or Igl
with IgH, Igk, or Igl variable region primers (Table S6) were PCR amplified in
a 50 ml reaction at 95C for 5 min, 94C for 30 s, 64C (Igk and Igl) or 62C
(IgH) for 45 s, 72C for 90 s for 35 cycles followed by one cycle of 72C for
7 min for IgH. Nested PCR was then performed in individual amplifications
with 3.0 ml of PCRproduct, 103PCRBuffer (QIAGEN), 103QBuffer (QIAGEN),
0.20 mM dNTPs (QIAGEN), MgCl2 (IgH 1.50 mM, Igk 1.00 mM, Igl 1.00 mM),
with 0.500 mMof IgH, or Igk, or Igl internal forward and reverse variable region
primers (Table S6). The nested PCR conditions were: 95C for 5 min, 94C for
30 s, 64C (Igk and Igl) or 62C (IgH) for 45 s, 72C for 90 s for 35 cycles fol-
lowed by one cycle of 72C for 7 min. PCR products were analyzed on 1.2%
SYBER Safe E-Gels (Invitrogen). VH and VL PCR-amplified genes were then
purified and sequenced, sequences were analyzed, and VDJ arrangements
were inferred with previously described computational methods (Kepler,
2013; Munshaw and Kepler, 2010).
Transient and Recombinant Antibody Expression
Transient and recombinant antibody expressions were performed as previ-
ously described (Liao et al., 2009, 2011).
ELISA
ELISA assays were performed as previously described (Liao et al., 2011). K169
sensitivity in the initial screen of transient transfected V2 antibodies was estab-
lished with ELISA by computing the area under the curve (AUC) for three serial
dilutions (1:1, 1:3, and 1:9) for antibody binding to wild-type 171 V2 peptide
and the K169A 171. Antibodies for which >50% reduction in K169A AUC rela-
tive toWTwas observedwere classified as K169 dependent. For epitopemap-
ping of purified antibodies, ELISA half-maximal effective concentrations
(EC50s) were calculated by curve fitting via a five parameter logistic model916 Immunity 41, 909–918, December 18, 2014 ª2014 Elsevier Inc.and epitope positions defined by V2 171 peptide alanine scan mutations
that reduced EC50s by >50% relative to wild-type. Site-directed mutagenesis
was performed as previous described (Gao et al., 2014).
Neutralization Assays
Neutralization activity of antibodies was measured in TMZ-bl cell-based (Sar-
zotti-Kelsoe et al., 2014) and A3R5.7 cell-based (McLinden et al., 2013)
neutralization assays.
SPR Kinetics Measurements
Epitope mapping experiments in SPR were performed on a BIAcore 4000
(BIAcore) instrument at 25C. Using a Series S CM5 chip, wild-type and ala-
substituted peptides were amine-coupled directly on the chip surface. Data
analyses were performed with the Biacore 4000 evaluation and BIAevaluation
4.1 software (BIAcore) as previously described (Alam et al., 2007, 2011). Bind-
ing responses of the irrelevant respiratory syncytial virus (RSV) antibody
Synagis was used to subtract out responses resulting from nonspecific inter-
actions. Antibodies 1056 and 1534 failed to bind the AE.A244 171 peptide in
ELISA assays but binding was detected with SPR and alanine scanning muta-
genesis SPRwas used to finemap the 1056 and 1534 epitopes with an epitope
inclusion criteria of >50% reduction in SPR response units relative to wild-type
peptide.
Sequence Analysis and Molecular Modeling
Details of the sequence analysis and molecular modeling performed are pro-
vided in the Supplemental Experimental Procedures.
Biolayer Interferometry Measurements
All biolayer interferometry (BLI) measurements were made with a ForteBio
OctetRed 96 instrument and streptavidin sensors at 25C and data analyses
were performed with ForteBio data analysis 7 software. The gp120165-182 pep-
tide sensors were prepared by dipping streptavidin sensors into wells contain-
ing biotinlyated gp120165-182 peptides (5 mg/ml) for 300 s. The peptide-loaded
sensors were washed in PBS buffer (pH 7.4) for 60 s before obtaining baseline.
The affinity measurements of the mature and UA Fabs of CH59 to the
gp120165-182 peptide were carried out by performing binding titrations (Fab
concentrations ranged from 1 to 50 mg/ml). The gp41 MPER-specific 13H11
Fab (1–20 mg/ml) binding to the WT peptide sensors was used in parallel to
subtract out binding resulting from nonspecific interactions with the sensors.
The subtracted binding curves were fitted globally to a 1:1 binding model to
obtain association (ka) and dissociation (kd) rate constants and the apparent
dissociation constant (Kd). The titrations were performed in triplicate.
Crystallographic Analysis of CH59-UA
Fab fragments of CH59-UA were produced recombinantly as previously
described (Nicely et al., 2010). In short, Fab chains were generated by PCR
with light and heavy chain genes as templates with appropriate primer pairs,
and cloned into pcDNA3.1/hygro (Liao et al., 2006). Recombinant Fabs were
produced in 293F cells by cotransfection with heavy chain and light chain
gene plasmids, then purified via the methods described previously (Nicely
et al., 2010). After affinity capture with CaptureSelect Fab lambda affinity ma-
trix [BAC] under standard conditions, the Fab was further purified via gel filtra-
tion chromatography with a HiLoad 26/60 Superdex 200pg 26/60 column at
2 ml/min with a buffer of 10 mM HEPES (pH 7.2), 50 mM NaCl, 0.02% NaN3.
Fab peak elution fractions were pooled and exchanged into ddH2O via five
dilute/concentrate cycles and brought to a final concentration of 15.0 mg/ml.
Unliganded Fab was tested in various crystallization screens in SBS format
with reservoir volumes of 60 ml and drop volumes of 0.6 ml. Plates were incu-
bated at 20C. Crystals of CH59-UA were observed over a reservoir of
0.05 M calcium chloride dihydrate, 0.1 M MES monohydrate (pH 6.0), 45%
PEG 200 in drops composed of 0.3 ml protein + 0.3 ml reservoir with the protein
solution at 15 mg/ml. These crystals were cryo-cooled directly from the drop.
Data on the crystal was collected at SER-CAT BM with an incident beam
with wavelength of 1 Å. Data were reduced in HKL-2000 (Otwinowski and Mi-
nor, 1997). Matthews analysis suggested two Fabs in the asymmetric unit of
the unliganded CH59-UA structure (Matthews, 1968). The structure was
phased by molecular replacement in PHENIX (Terwilliger et al., 2008) with as
the sourcemodel the mature CH59 Fab structure (Liao et al., 2013). Rebuilding
Immunity
Phylogenetic Conservation of HIV-1 V2 Recognitionand real-space refinements were done in Coot (Emsley et al., 2010) with recip-
rocal space refinements in PHENIX (Adams et al., 2010) and validations inMol-
Probity (Lovell et al., 2003). The crystal structure of unliganded CH59-UA Fab
was refined to a resolution of 2.4 Å (Table S1).
ACCESSION NUMBERS
The GenBank accession numbers for VH and VL sequences of the rhesus an-
tibodies reported in this paper are KJ956810–KJ956891. Coordinates and
structure factors for CH59-UA have been deposited into the Protein Data
Bank with accession code 4QF1.
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